Compare BTZ & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTZ | CSTL |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.6M | 806.3M |
| IPO Year | N/A | 2019 |
| Metric | BTZ | CSTL |
|---|---|---|
| Price | $10.02 | $25.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $47.17 |
| AVG Volume (30 Days) | 307.3K | ★ 397.3K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 9.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.10 |
| Revenue Next Year | N/A | $12.63 |
| P/E Ratio | $7.14 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $9.54 | $14.59 |
| 52 Week High | $11.18 | $44.28 |
| Indicator | BTZ | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 17.83 | 26.28 |
| Support Level | N/A | $21.77 |
| Resistance Level | $10.84 | $34.97 |
| Average True Range (ATR) | 0.10 | 1.38 |
| MACD | -0.06 | -0.09 |
| Stochastic Oscillator | 2.76 | 7.96 |
Blackrock Credit Allocation Income Trust is a diversified, closed-end Trust engaged in providing investment advisory and risk management solutions. Its investment objective is to seek current income, current gains, and capital appreciation. The company invests under normal market conditions, at least 80% of its assets in credit-related securities, including, but not limited to, investment-grade corporate bonds, high-yields, bank loans, preferred securities or convertible bonds, or derivatives with economic characteristics similar to these credit-related securities.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.